Last reviewed · How we verify
Ropivacaine Hcl 0.2% Inj Vil 10Ml
Ropivacaine Hcl 0.2% Inj Vil 10Ml is a Small molecule drug developed by Surgery Bitenc. It is currently in Phase 1 development.
At a glance
| Generic name | Ropivacaine Hcl 0.2% Inj Vil 10Ml |
|---|---|
| Sponsor | Surgery Bitenc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Efficacy of Continous Regional Anesthesia Using m. Erector Spinae Catheter After VATS Procedures (NA)
- Incidence Of Hemidiaphragmatic Paralysis After Usg Guided Low Dose Interscalene Brachial Plexus Block (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ropivacaine Hcl 0.2% Inj Vil 10Ml CI brief — competitive landscape report
- Ropivacaine Hcl 0.2% Inj Vil 10Ml updates RSS · CI watch RSS
- Surgery Bitenc portfolio CI
Frequently asked questions about Ropivacaine Hcl 0.2% Inj Vil 10Ml
What is Ropivacaine Hcl 0.2% Inj Vil 10Ml?
Ropivacaine Hcl 0.2% Inj Vil 10Ml is a Small molecule drug developed by Surgery Bitenc.
Who makes Ropivacaine Hcl 0.2% Inj Vil 10Ml?
Ropivacaine Hcl 0.2% Inj Vil 10Ml is developed by Surgery Bitenc (see full Surgery Bitenc pipeline at /company/surgery-bitenc).
What development phase is Ropivacaine Hcl 0.2% Inj Vil 10Ml in?
Ropivacaine Hcl 0.2% Inj Vil 10Ml is in Phase 1.